<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03397706</url>
  </required_header>
  <id_info>
    <org_study_id>VT3996-201</org_study_id>
    <nct_id>NCT03397706</nct_id>
  </id_info>
  <brief_title>Dose Escalation &amp; Expansion Study of Oral VRx-3996 &amp; Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies</brief_title>
  <official_title>A Phase 1b/2 Open-Label, Dose Escalation &amp; Expansion Study of Orally Administered VRx-3996 &amp; Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viracta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viracta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination
      with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in
      relapsed/refractory EBV+ lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether VRx-3996 in combination with valganciclovir
      is safe, determine the side effect profile, and to determine whether this therapy may help
      patients with EBV-related lymphomas. The study has two phases. Goals of the first phase
      include determining a safe and tolerable dose that can be administered in phase 2. Goals of
      the second phase include further evaluating the safety and tolerability of VRx-3996 in
      combination with valganciclovir, evaluating how the drugs are metabolized in the body,
      evaluating response rates and other exploratory objectives that will help the researchers
      evaluate how these drugs work in the body. Participants will receive daily oral doses of the
      two study drugs and will have multiple study visits where they will have blood collected,
      physical examinations, and other medical monitoring.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1: dose escalation phase (3+3 design with definitions of dose limiting toxicity) to define a recommended phase 2 dose
Phase 2: dose expansion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events and changes in clinical safety laboratory values in Dose Escalation and Cohort Expansion</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Determination of a safe and tolerable Recommended Phase 2 Dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities in Dose Escalation and Cohort Expansion</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Determine safety and tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR as measured by stable disease (SD), partial response (PR), and complete response (CR) by radiographic assessment</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Disease response will be assessed using a combination of physical exam and imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single-dose and steady-state Cmax of VRx-3996 and valganciclovir</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>PK assessment of both VRx-3996 and valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1 and C2 D1 and pre-dose and at hour 2 on C1D2 ,C1D15, and C2D15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose and steady-state AUC of VRx-3996 and valganciclovir</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>PK assessment of both VRx-3996 and valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1 and C2 D1 and pre-dose and at hour 2 on C1D2 ,C1D15, and C2D15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state elimination half-life of VRx-3996 and valganciclovir</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>PK assessment of both VRx-3996 and valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1 and C2 D1 and pre-dose and at hour 2 on C1D2, C1D15, and C2D15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>The time from the start of first study drug administration to the first overall tumor response observed for subjects who achieved a CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>The time interval (days) from date of the first overall response (CR or PR; achieved after study drug administration) to the date of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>The interval between the date of first study drug administration and the date of PD or death, whichever is first reported</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Epstein-Barr Virus Associated Lymphoma</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <arm_group>
    <arm_group_label>Phase 1b Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VRx-3996 (cohort 1) and valganciclovir
VRx-3996 (cohort 2) and valganciclovir
VRx-3996 (cohort 3) and valganciclovir
VRx-3996 (cohort 4) and valganciclovir
VRx-3996 (cohort 5) and valganciclovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VRx-3996</intervention_name>
    <description>capsules taken orally once or twice daily</description>
    <arm_group_label>Phase 1b Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>tablets taken orally once or twice daily</description>
    <arm_group_label>Phase 1b Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Relapsed/refractory, pathologically confirmed EBV+ lymphoid malignancy or
             lymphoproliferative disease

          -  Absence of available therapy with reasonable likelihood of cure or significant
             clinical benefit

          -  Adequate hematologic, hepatic and renal function as defined by laboratory assessment

        Key Exclusion Criteria:

          -  Known primary CNS lymphoma

          -  Known CNS metastases or leptomeningeal disease unless appropriately treated and
             neurologically stable for at least 4 weeks

          -  Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic
             therapy

          -  Refractory graft versus host disease (GvHD) not responding to treatment

          -  Known active hepatitis B virus infection

          -  Circulating hepatitis C virus on qPCR

          -  Known history of HHV-6 chromosomal integration

          -  Known history of HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert McRae</last_name>
    <role>Study Director</role>
    <affiliation>Viracta Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert McRae, Vice President, Operations</last_name>
    <phone>858-400-8470</phone>
    <email>ClinicalTrials@Viracta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Duran, Study Coordinator</last_name>
      <phone>323-865-0371</phone>
      <email>duran_c@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anil Tulpule, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Perez</last_name>
      <phone>714-509-2414</phone>
      <email>michelrp@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Brem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Massingill</last_name>
      <phone>720-848-0736</phone>
      <email>Justin.Massingill@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley Haverkos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Florida Hematology and Oncology Center</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahesh Nelakurthi</last_name>
      <phone>386-774-1223</phone>
      <phone_ext>175</phone_ext>
      <email>mahesh@aorcorp.com</email>
    </contact>
    <investigator>
      <last_name>Santosh Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASCLEPES Research Centers</name>
      <address>
        <city>Weeki Wachee</city>
        <state>Florida</state>
        <zip>34607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Leonard, RN, BSN</last_name>
      <phone>352-364-9401</phone>
      <email>kleonard@asclepes.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Alan Kerr II, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Durden</last_name>
      <phone>706-721-0660</phone>
      <email>CRDurden@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Locke Bryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reem Karmali, MD, MS</last_name>
      <phone>312-695-0990</phone>
      <email>reem.karmali@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Reem Karmali, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruth M Rothstein CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mieoak Bahk</last_name>
      <phone>312-572-4543</phone>
      <email>mbahk@cookcountyhhs.org</email>
    </contact>
    <investigator>
      <last_name>Paul Rubenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Coleman</last_name>
      <phone>317-528-7298</phone>
      <email>melanie.coleman@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>John Edwards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center and Medical Pavilion</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Kelly, Study Coordinator</last_name>
      <phone>913-588-2545</phone>
      <email>ekelly4@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Anusha Vallurupalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Clark, Study Nurse</last_name>
      <phone>410-502-5396</phone>
      <email>lclark53@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Ambinder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijayalakshmi Donthireddy, MD</last_name>
      <email>vdonthi1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Marjorie Wood</last_name>
    </contact_backup>
    <investigator>
      <last_name>Vijayalakshmi Donthireddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Healthcare Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Erhardt</last_name>
      <phone>406-238-6962</phone>
      <email>tina.erhardt@sclhealth.org</email>
    </contact>
    <investigator>
      <last_name>Patrick Cobb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack UMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Kdiry</last_name>
      <phone>551-996-5952</phone>
      <email>Sabrina.Kdiry@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Tatyana Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College - New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bourke, Research Nurse</last_name>
      <phone>212-746-2844</phone>
      <email>jeb9097@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Koen van Besien, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Jenkins</last_name>
      <phone>614-366-0855</phone>
      <email>cynthia.jenkins@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Polina Shindiapina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariel Kobylak</last_name>
      <phone>215-955-2810</phone>
      <email>Ariel.Kobylak@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Onder Alpdogan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lovlei McKinnie</last_name>
      <phone>215-214-3173</phone>
      <email>Lovlei.McKinnie@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Asya Varshavsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Hematologia e Oncologia da Bahia (CEHON)</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>40110-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Débora Santos</last_name>
      <phone>+55 (71) 3281-6484</phone>
      <email>debora.santos@clinicacehon.com.br</email>
    </contact>
    <investigator>
      <last_name>Ana Luzia Schriefer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Cancer de Pernambuco (HCP)</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <zip>50040-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeria Lobo Tavares</last_name>
      <phone>+55 (71) 3217-8084</phone>
    </contact>
    <contact_backup>
      <last_name>Livia Tavares de Oliveira</last_name>
      <phone>+55 (71) 3217-8084</phone>
    </contact_backup>
    <investigator>
      <last_name>Reijane Assis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital do Cancer Mae de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Alerico</last_name>
      <phone>+55 (51) 3234-4345</phone>
      <email>alerico.pesquisa@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marcelo Capra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Real e Benemerita Associacao Portuguesa de Beneficencia</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01321-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gislaine Mancin</last_name>
      <phone>+55 (11) 3505-6675</phone>
      <email>gislaine.mancin@bp.org.br</email>
    </contact>
    <investigator>
      <last_name>Phillip Scheinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maris Sugino</last_name>
      <phone>+55 (11) 4573-7631</phone>
      <email>maris.sugino@hc.fm.usp.br</email>
    </contact>
    <investigator>
      <last_name>Juliana Pereira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Opazo</last_name>
      <phone>+55 (11) 2217-3766</phone>
      <email>carlos.opazocpc@santamarcelina.org</email>
    </contact>
    <investigator>
      <last_name>Jose Oliveira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.viracta.com/</url>
    <description>Viracta Therapeutics, Inc.</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EBV+ post-transplant lymphoproliferative malignancy</keyword>
  <keyword>EBV-associated lymphoproliferative disorders associated with acquired immunodeficiency</keyword>
  <keyword>Relapsed, refractory, EBV+ lymphoid malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

